Table 3 Clinical characteristics of the prostate cancer tumour samples in three TCGA-PRAD sets
Clinical feature | Training set | Validation set | Complete set |
|---|---|---|---|
TCGA-PRAD (n = 248) | TCGA-PRAD (n = 108) | TCGA-PRAD (n = 356) | |
Age (year) (%) | |||
 < 60 | 87 (35.1) | 46 (42.6) | 133 (37.4) |
 ≥ 60 | 161 (64.9) | 62 (57.4) | 223 (62.6) |
Biochemical recurrence events (%) | 49 (19.8) | 15 (13.9) | 64 (18.0) |
Pathological T stage (%) | |||
T2 | 85 (34.3) | 33 (30.6) | 118 (33.1) |
T3-4 | 163 (65.7) | 75 (69.4) | 238 (66.9) |
Pathological N stage (%) | |||
N0 | 205 (82.7) | 85 (78.7) | 290 (81.5) |
N1 | 43 (17.3) | 23 (21.3) | 66 (18.5) |
Gleason score (%) | |||
 ≤ 7 | 130 (52.4) | 59 (54.6) | 189 (53.1) |
 > 7 | 118 (47.6) | 49 (45.4) | 167 (46.9) |